Aminocarbonylcarbamate compounds
AssigneeSK Biopharmaceuticals Co., Ltd.
InventorsYoung-Soon Kang, Jin-Yong Chung, Cheol-Young Maeng, Han-Ju Yi, Ki-Ho Lee, Joon Heo, Eun-Hee Chae, Yu-Jin Shin
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.
Claims20
A method for treating dopamine reuptake-related diseases or promoting smoking cessation comprising:
- administering to a mammal in need thereof a therapeutically effective amount of a compound of Formula (I) or pharmaceutically acceptable salt thereof,
- wherein
- X is independently halo, alkyl, alkoxy or nitro;
- m is 0, 1, 2, 3 or 4
- n is 1 or 2;
- R1 and R2 are independently H— or alkyl;
- R3 is H—, alkyl or aralkyl;
- and
- R4 is H— or aryl,
- wherein at least one of R1, R2, R3 and R4 is not H—,
- wherein the dopamine reuptake-related disease is selected from the group consisting of fatigue, obesity, narcolepsy, fibromyalgia, cataplexy, drug addiction, sexual dysfunction, restless legs syndrome, bipolar disorder, depression, excessive daytime sleepiness, obsessive-compulsive disorder, and binge eating disorder.
A method for treating dopamine reuptake-related diseases or promoting smoking cessation comprising:
- administering to a mammal in need thereof a therapeutically effective amount of a compound selected from the group consisting of:
- 2-amino-3-(2-chlorophenyl)propyl (aminocarbonyl)carbamate;
- 2-amino-3-(2,4-dichlorophenyl)propyl (aminocarbonyl)carbamate;
- 2-amino-3-(3,4-dichlorophenyl)propyl (aminocarbonyl)carbamate;
- 2-amino-3-(4-chlorophenyl)propyl (aminocarbonyl)carbamate;
- 2-amino-3-(3-chlorophenyl)propyl (aminocarbonyl)carbamate;
- 2-amino-3-(4-nitrophenyl)propyl (aminocarbonyl)carbamate;
- 2-amino-3-(4-tert-butylphenyl)propyl (aminocarbonyl)carbamate;
- 2-amino-3-(2-fluorophenyl)propyl (aminocarbonyl)carbamate;
- (2R)-2-amino-3-(2-chlorophenyl)propyl (aminocarbonyl)carbamate;
- (2R)-2-amino-3-(2,4-dichlorophenyl)propyl (aminocarbonyl)carbamate;
- (2R)-2-amino-3-(3,4-dichlorophenyl)propyl (aminocarbonyl)carbamate;
- 2-amino-3-phenylpropyl(aminocarbonyl)carbamate;
- (2R)-2-amino-3-phenylpropyl(aminocarbonyl)carbamate;
- and
- a pharmaceutically acceptable salt thereof;
- and
- wherein the dopamine reuptake-related disease is selected from the group consisting of fatigue, obesity, narcolepsy, fibromyalgia, cataplexy, drug addiction, sexual dysfunction, restless legs syndrome, bipolar disorder, depression, excessive daytime sleepiness, obsessive-compulsive disorder, and binge eating disorder.
Dependencies are inferred from the claim text.